CALIFORNIA RETINA CONSULTANTS
Clinical Trials
10
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Povidone Iodine vs AVEnova: A Pre-injection Disinfection Study (PAVE Study)
- Conditions
- Diabetic RetinopathyDiabetic Macular EdemaAge-related Macular Degeneration
- First Posted Date
- 2019-07-12
- Last Posted Date
- 2020-03-10
- Lead Sponsor
- California Retina Consultants
- Target Recruit Count
- 50
- Registration Number
- NCT04018482
- Locations
- 🇺🇸
California Retina Consultants, Santa Barbara, California, United States
Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema
- Conditions
- Diabetic Macular Edema
- Interventions
- Drug: Intravitreal anti-VEGF injection
- First Posted Date
- 2015-06-15
- Last Posted Date
- 2019-02-19
- Lead Sponsor
- California Retina Consultants
- Target Recruit Count
- 40
- Registration Number
- NCT02471651
- Locations
- 🇺🇸
California Retina Consultants, Santa Maria, California, United States
Variable Interval Versus Set Interval Aflibercept for DME
- Conditions
- Cystoid Macular EdemaDiabetic Macular Edema
- Interventions
- First Posted Date
- 2015-03-19
- Last Posted Date
- 2019-01-03
- Lead Sponsor
- California Retina Consultants
- Target Recruit Count
- 50
- Registration Number
- NCT02392364
- Locations
- 🇺🇸
California Retina Consultants - Bakersfield, Bakersfield, California, United States
🇺🇸California Retina Consultants - Santa Barbara Office, Santa Barbara, California, United States
Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF
- Conditions
- Diabetic Macular EdemaRetinal Vein OcclusionAge-related Macular Degeneration
- Interventions
- First Posted Date
- 2014-04-21
- Last Posted Date
- 2016-05-19
- Lead Sponsor
- California Retina Consultants
- Target Recruit Count
- 56
- Registration Number
- NCT02118831
Performance Assessment Tests in Working Individuals With DME Following Treatment With Ranibizumab
- First Posted Date
- 2014-04-08
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- California Retina Consultants
- Target Recruit Count
- 40
- Registration Number
- NCT02107131
- Locations
- 🇺🇸
California Retina Consultants - Bakersfield, Bakersfield, California, United States
🇺🇸California Retina Consultants, Visalia, California, United States
🇺🇸California Retina Consultants - Santa Barbara Office, Santa Barbara, California, United States
- Prev
- 1
- 2
- Next
News
HELIOS Trial Shows Promise: OTX-TKI Demonstrates Positive Results for Diabetic Retinopathy Treatment
The HELIOS trial revealed OTX-TKI was well-tolerated with no serious adverse events, with all diabetic retinopathy severity score improvements occurring in the treatment arm and all worsening in the sham arm.
Phase 1 HELIOS Trial Shows Promise for OTX-TKI in Non-Proliferative Diabetic Retinopathy
Interim 48-week data from the Phase 1 HELIOS trial demonstrates that a single injection of OTX-TKI (sustained-release axitinib implant) prevented disease progression in patients with moderately severe to severe non-proliferative diabetic retinopathy.